Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and Inlyta in FH-deficient Renal Cell Carcinoma
NCT04387500Phase 2Active, not recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2021
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Fumarate hydratase-deficient renal cell carcinoma (FH-RCC), sponsored by West China Hospital of Sichuan University. Started Jul 2021; status: active, not recruiting.
02
Drugs
sintilimab
03
Conditions
Fumarate hydratase-deficient renal cell carcinoma (FH-RCC)
Beyond the preview
Go deeper on NCT04387500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04387500.